McQuade is very pro hard work, research and analysis. He is very negative on people pointing fingers at others to justify their own mistakes. He is also negative on those wanting the information off those who do the hard work only to denigrate the work put in.
I have zero relationship with Newing apart from buying the last piece of research for $20. I agree with a lot of what he wrote but disagree with other bits. Forecasts are opinions so we can all have a guess. But his are based on a lot of work over a long period of time.
Others on here are based on emotion, anger and frustration…but zero actual work.
That’s my position @ChristopherC and you could’ve asked me directly.
- Forums
- ASX - By Stock
- PET
- Ann: FY 2021 Business Review and Strategic Outlook Webinar
Ann: FY 2021 Business Review and Strategic Outlook Webinar, page-61
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PET (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.60M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
PET (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online